Ocugen Reports $24.9 Million Net Loss in Q2 2026, Revenue Increases to $1.5 Million

Ocugen, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $24.9 million, compared to a net loss of $14.7 million for the same period in 2025. For the six months ended June 30, 2026, the company incurred a net loss of $44.1 million, up from $30.1 million in the prior year. Total revenue for the second quarter was $1.5 million, a slight increase from $1.4 million in the same quarter last year, driven primarily by collaborative arrangement revenue, which rose to $1.5 million from $1.4 million.

The company's operating expenses increased to $17.9 million in the second quarter of 2026, compared to $15.2 million in the same quarter of 2025. This rise was attributed to higher research and development costs, which reached $10.7 million, up from $8.4 million, largely due to increased personnel costs and expenses related to clinical trials for its product candidates OCU410 and OCU410ST. General and administrative expenses also saw an uptick, totaling $7.2 million, compared to $6.8 million in the previous year.

Significant strategic developments included the completion of a private offering of $130 million in convertible notes in May 2026, which generated net proceeds of approximately $112.5 million after expenses. The company utilized about $32.7 million of these proceeds to fully repay its Avenue Capital Loan, thereby strengthening its financial position. As of June 30, 2026, Ocugen reported cash and cash equivalents of $100.1 million, a substantial increase from $18.6 million at the end of 2025.

Operationally, Ocugen is advancing its clinical programs, with the Phase 3 trial for OCU400 for retinitis pigmentosa now fully enrolled, and topline data expected in early 2027. The company also initiated the GARDian3 pivotal confirmatory trial for OCU410ST in July 2025, with plans to submit a Biologics License Application (BLA) for this product by mid-2027. The company’s employee headcount has increased as it continues to expand its research and development capabilities.

Looking ahead, Ocugen's management expressed concerns regarding its ability to continue as a going concern, citing ongoing operating losses and the need for additional financing to support its operations and product development. The company is exploring various strategies, including potential partnerships and licensing arrangements, to mitigate these challenges.